Madison Elsaadi
Stock Analyst at B. Riley Securities
(4.40)
# 1,258
Out of 5,078 analysts
67
Total ratings
42.6%
Success rate
23.9%
Average return
Main Sectors:
Stocks Rated by Madison Elsaadi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Reiterated: Buy | $22 | $3.18 | +591.82% | 16 | Oct 12, 2026 | |
| OBIO Orchestra BioMed Holdings | Reiterated: Buy | $11 | $5.59 | +96.78% | 2 | Oct 2, 2026 | |
| ANIK Anika Therapeutics | Initiated Coverage: Buy | $23 | $21.42 | +7.38% | 1 | Sep 18, 2026 | |
| CAPR Capricor Therapeutics | Upgraded: Buy | $5 → $21 | $5.93 | +254.13% | 8 | Sep 14, 2026 | |
| STIM Neuronetics | Initiated Coverage: Buy | $5 | $2.11 | +136.97% | 1 | Sep 11, 2026 | |
| VNDA Vanda Pharmaceuticals | Initiated Coverage: Buy | $17 → $12 | $4.01 | +199.25% | 6 | Aug 10, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $17 → $22 | $11.18 | +96.78% | 2 | Aug 6, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterated: Buy | $123 | $58.02 | +112.00% | 7 | Aug 5, 2026 | |
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $160 | $45.15 | +254.37% | 1 | Jul 13, 2026 | |
| ETON Eton Pharmaceuticals | Reiterated: Buy | $40 | $50.00 | -20.00% | 14 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $2.16 | +131.48% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 → $10 | $3.47 | +188.18% | 2 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $16 | $10.08 | +58.73% | 1 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $179 | $145.04 | n/a | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $6.33 | n/a | 1 | Jan 23, 2025 |
Wave Life Sciences
Oct 12, 2026
Reiterated: Buy
Price Target: $22
Current: $3.18
Upside: +591.82%
Orchestra BioMed Holdings
Oct 2, 2026
Reiterated: Buy
Price Target: $11
Current: $5.59
Upside: +96.78%
Anika Therapeutics
Sep 18, 2026
Initiated Coverage: Buy
Price Target: $23
Current: $21.42
Upside: +7.38%
Capricor Therapeutics
Sep 14, 2026
Upgraded: Buy
Price Target: $5 → $21
Current: $5.93
Upside: +254.13%
Neuronetics
Sep 11, 2026
Initiated Coverage: Buy
Price Target: $5
Current: $2.11
Upside: +136.97%
Vanda Pharmaceuticals
Aug 10, 2026
Initiated Coverage: Buy
Price Target: $17 → $12
Current: $4.01
Upside: +199.25%
COMPASS Pathways
Aug 6, 2026
Reiterated: Buy
Price Target: $17 → $22
Current: $11.18
Upside: +96.78%
Arrowhead Pharmaceuticals
Aug 5, 2026
Reiterated: Buy
Price Target: $123
Current: $58.02
Upside: +112.00%
Spruce Biosciences
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $160
Current: $45.15
Upside: +254.37%
Eton Pharmaceuticals
Jun 25, 2026
Reiterated: Buy
Price Target: $40
Current: $50.00
Upside: -20.00%
May 13, 2026
Reiterated: Buy
Price Target: $5
Current: $2.16
Upside: +131.48%
Apr 30, 2026
Reiterated: Buy
Price Target: $9 → $10
Current: $3.47
Upside: +188.18%
Feb 12, 2026
Initiated Coverage: Buy
Price Target: $16
Current: $10.08
Upside: +58.73%
Oct 1, 2025
Initiated Coverage: Buy
Price Target: $179
Current: $145.04
Upside: n/a
Jan 23, 2025
Reiterated: Buy
Price Target: $11
Current: $6.33
Upside: n/a